Study guide
7.2 Clinical Guidelines and Standards of Care
ANCC Family Nurse Practitioner FNP-BC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Application, and Test Day 1.3 Blueprint Weights, TCO Dates, and Study Strategy
2 Assessment Foundations
2.1 Population Health Promotion and Screening 2.2 Comprehensive History and Physical 2.3 Focused History and Physical 2.4 Age-Specific Screening Schedules
3 Function, Risk, and Lifespan Assessment
3.1 Functional Assessment 3.2 Risk Assessment and Social Determinants 3.3 Pediatric Developmental Assessment 3.4 Adolescent, Adult, and Geriatric Assessment
4 Diagnosis Foundations
4.1 Pathogenesis and Pathophysiology 4.2 Diagnostic Test and Procedure Selection 4.3 Interpreting Labs and Imaging 4.4 Normal vs Abnormal Physiologic Change
5 Differential Diagnosis
5.1 Formulating Differential Diagnoses 5.2 Red Flags and Emergency Identification 5.3 Diagnostic Reasoning Traps
6 Prevention and Anticipatory Guidance
6.1 Primary, Secondary, and Tertiary Prevention 6.2 Pediatric and Adolescent Anticipatory Guidance 6.3 Adult and Geriatric Anticipatory Guidance 6.4 Immunization Planning Across the Lifespan
7 Guidelines, Culture, and Evidence
7.1 Crisis, Safety, and End-of-Life Planning 7.2 Clinical Guidelines and Standards of Care 7.3 Culturally and Ethnically Sensitive Practice 7.4 Evidence-Based Research Appraisal
8 Care Plans and Shared Decisions
8.1 Shared Decision-Making 8.2 Multimorbidity and Prioritization 8.3 Referral, Comanagement, and Transitions
9 Pharmacotherapeutics
9.1 Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics 9.2 Interactions, Contraindications, and Monitoring 9.3 Special-Population Prescribing 9.4 High-Alert Medications and Analgesic Safety
10 Cardiovascular Primary Care
10.1 Cardiovascular Diagnosis 10.2 Cardiovascular Pharmacotherapy 10.3 Nonpharmacologic Cardiovascular Management 10.4 Lifespan Cardiovascular Issues
11 Respiratory Primary Care
11.1 Respiratory Diagnosis 11.2 Respiratory Pharmacotherapy 11.3 Lifespan Respiratory Care
12 Endocrine and Metabolic Primary Care
12.1 Diabetes Diagnosis and Monitoring 12.2 Diabetes Pharmacotherapy 12.3 Thyroid and Other Endocrine Disorders 12.4 Obesity and Metabolic Disease
13 Gastrointestinal Primary Care
13.1 Gastrointestinal Diagnosis 13.2 GI Pharmacotherapy and Nutrition 13.3 Lifespan Gastrointestinal Care
14 GU, Renal, and Reproductive Primary Care
14.1 GU and Renal Diagnosis and Management 14.2 Women's Reproductive Health 14.3 Pregnancy and Postpartum Primary Care 14.4 Men's Health and Sexual Function
15 HEENT, Skin, and Musculoskeletal
15.1 HEENT Diagnosis and Management 15.2 Integumentary Diagnosis and Management 15.3 Musculoskeletal Diagnosis 15.4 MSK Procedures and Nonpharmacologic Care
16 Neuro, Psych, Heme, Immune, and Infection
16.1 Neurological Diagnosis and Management 16.2 Psychiatric Diagnosis and Substance Use 16.3 Hematopoietic and Immune Disorders 16.4 Common Infections and Anti-Infectives
17 Clinical Delivery Skills
17.1 Office Procedures and Nonpharmacologic Treatment 17.2 Patient-Specific Education 17.3 Therapeutic Communication 17.4 Comprehensive Documentation
18 Professional Practice
18.1 Legal and Ethical Implications 18.2 Health IT, EHR, and AI Ethics 18.3 Regulatory Guidelines: Reportable Disease and Abuse 18.4 APRN Scope, Standards, and FNP Role
19 Outcome Evaluation
19.1 Ethical and Legal Evaluation Issues 19.2 Pharmacotherapeutic Outcome Monitoring 19.3 Nonpharmacologic Outcome Monitoring 19.4 Clinical Data, PROs, and Treatment Efficacy
20 Follow-Up, Systems, and Exam Strategy
20.1 Follow-Up Intervals and Surveillance 20.2 Treatment Adjustment and Deprescribing 20.3 Resource Management and Care Coordination 20.4 Exam-Day Strategy and TCO Review
7.2 Clinical Guidelines and Standards of Care
Key Takeaways Explain This Topic AI
Choose the most recent applicable U.S. guideline from the condition owner: USPSTF for screening, ACIP for vaccines, ADA for diabetes, 2025 AHA/ACC for hypertension, GOLD for COPD, GINA for current asthma therapy, IDSA for many infections, and CDC MEC / ACOG for contraception.
The 2025 AHA/ACC hypertension guideline uses PREVENT risk, a blood-pressure goal below 130/80 for most adults, and race-neutral first-line therapy with a thiazide, ACE inhibitor, ARB, or dihydropyridine CCB.
GINA 2025/2026: every adolescent and adult with asthma needs ICS-containing therapy; Track 1 ICS-formoterol AIR/MART is preferred; SABA-only is not a plan.
When reputable U.S. guidelines conflict (ACS versus USPSTF mammography), document shared decision-making rather than inventing a third schedule from a blog.
ANCC items follow U.S. primary-care consensus. A guideline informs the standard of care; it is not automatically a statute. Document the rationale when you deviate.
Last updated: August 2026
Official TCO knowledge in Domain III Planning includes evidence-based clinical guidelines and standards of care . ANCC is not asking you to memorize every footnote of every society PDF. It is asking you to know which U.S. authority owns the condition , to use the most recent applicable document from that owner, and to build a plan a reasonably prudent family NP would write — not a plan copied from a wellness blog or a 2012 pocket card.
How an FNP chooses a guideline
Start with the question type , then open the condition owner :
- Clinical question Go-to U.S. (or U.S.-used) guideline
- Screening an asymptomatic person USPSTF (grade, interval, age, stop rules)
- Immunization schedule, catch-up, pregnancy vaccines ACIP / CDC
Type 1 or type 2 diabetes diagnosis thresholds, A1c targets, organ-protective drugs ADA Standards of Care (current year)
- Hypertension diagnosis, PREVENT risk, drug class, BP goal 2025 AHA/ACC high blood pressure guideline
- COPD grouping, inhaler ladder, exacerbation plan GOLD report
Asthma controller / reliever strategy GINA 2025/2026 (ICS for all adolescents/adults; Track 1 ICS-formoterol). Cite NAEPP/EPR only if the stem names NHLBI
- CAP, cellulitis, cystitis, C. difficile, many SSTIs IDSA plus the local antibiogram
- Who may use which contraceptive CDC Medical Eligibility Criteria (MEC) ; ACOG for obstetric practice
- Heart failure, lipids, atrial fibrillation, stable CAD AHA/ACC condition-owner documents
- CKD staging and kidney-protective therapy KDIGO (with ADA when diabetes is the driver)
Breast or cervical screening when bodies disagree USPSTF as the primary-care default; ACS / ACOG as the other U.S. voice — then shared decision-making
The exam rule of thumb: most recent applicable specialty guideline from the condition owner. Screening is USPSTF even if a cardiology blog “screens” everyone with a coronary calcium score. Vaccines are ACIP even if a school form is outdated. Diabetes drug selection is ADA (and the relevant kidney or heart guideline when the comorbidity is the reason for the drug). ANCC items usually follow U.S. primary-care consensus , not a European-only oddity and not a manufacturer slide deck.
Standards of care are what a reasonably prudent FNP in similar circumstances would do. Guidelines inform that standard; they are not automatically statutes. When you deviate — a 78-year-old who declines colonoscopy after a real risk-benefit talk — document the shared decision and the reason. When two reputable U.S. bodies conflict, the plan is not “pick the one you memorized in 2018.” The plan is to name the conflict, use the stem’s stated authority if it names one, and otherwise document shared decision-making .
Hypertension: 2025 AHA/ACC, PREVENT, race-neutral first line
This is the high-yield Planning update.
Confirm hypertension with out-of-office measurements before labeling, unless the reading is a hypertensive emergency or the patient already has convincing end-organ disease.
Categories still use 130/80 as the treatment-relevant cut: elevated 120–129 / <80; stage 1 130–139 or 80–89; stage 2 ≥140 or ≥90.
The goal for most adults is <130/80 , if tolerated.
Risk discussion uses the PREVENT calculator, not the retired Pooled Cohort Equations as the 2025 text’s preferred engine.
Lifestyle (sodium, weight, activity, alcohol, potassium-rich diet or a potassium-containing salt substitute when potassium and kidney function allow) is on every plan.
First-line drugs: a thiazide-type diuretic , an ACE inhibitor , an ARB , or a dihydropyridine CCB , unless a compelling indication (HFrEF, albuminuric CKD, angina) chooses the class for you. Do not combine an ACE inhibitor with an ARB.
First-line selection is race-neutral. Do not automatically write “Black patient, therefore CCB or thiazide only” as if race were a pharmacokinetic lab value. Treat the blood pressure, the comorbidities, and the whole-drug plan.
Stage 2 usually starts pharmacotherapy (often two agents from different first-line classes if the reading is well into stage 2). Stage 1 starts medication when clinical CVD, diabetes, CKD, or elevated PREVENT 10-year risk as the current AHA/ACC text defines it is present. Use the threshold printed in the guideline or the stem; do not invent a private number.
Asthma: GINA 2025/2026 — no SABA-only
For adolescents and adults , every patient with asthma needs ICS-containing therapy. Track 1 , preferred: ICS-formoterol as the anti-inflammatory reliever (AIR) and, when symptoms are more frequent, as maintenance-and-reliever therapy (MART) . SABA-only treatment is not recommended — it is the classic outdated plan and a common exam trap. Track 2 (daily ICS plus a SABA reliever, or ICS whenever SABA is used) exists when Track 1 is not available or not accepted. Children have age-banded GINA tracks; do not copy the adult MART inhaler onto a preschooler without the pediatric table.
NAEPP/EPR-3 is older U.S. language (SABA plus stepped ICS). If a stem says “current GINA” or simply describes an adult who wants “just my albuterol,” the correct plan is ICS-containing therapy, preferably ICS-formoterol AIR/MART .
Other condition-owner rules worth a Planning item
GOLD COPD. Group by symptoms and exacerbations (A / B / E in current GOLD). Group E (exacerbations) is dual long-acting bronchodilation, with ICS added when blood eosinophils and exacerbation history support it — not a steroid inhaler for every smoker with a cough. Write the action plan (Section 7.1).
ADA diabetes. Diagnostic cutoffs (A1c ≥6.5%, fasting glucose ≥126 mg/dL, random ≥200 mg/dL with symptoms, or 2-hour OGTT ≥200) are Diagnosis. Planning is the A1c target (often <7% for many nonpregnant adults, individualized higher in frailty or limited life expectancy), metformin when appropriate, and organ-protective agents (SGLT2 inhibitor, GLP-1 receptor agonist) when heart failure, CKD, or atherosclerotic disease drives the choice — comorbidity, not a slogan, picks the drug.
ACIP. Build the schedule from the current child or adult schedule (Section 6.4). Package inserts and school forms lose when they disagree with ACIP.
CDC MEC / ACOG. MEC category 1 = no restriction, 2 = advantages outweigh risks, 3 = risks outweigh advantages (use only if no better method), 4 = unacceptable risk. Combined hormonal contraception is category 4 in several migraine-with-aura and early-postpartum settings — look up the condition; do not guess a category from memory if the stem is exotic.
IDSA. Use it when the stem is infection management (duration, first-line oral agent, when to image). Then check the local antibiogram . A 3-day nitrofurantoin plan for simple cystitis in a nonpregnant woman is an IDSA-shaped plan; 14 days of fluoroquinolone for the same syndrome is not.
USPSTF. Eligibility, grade, and interval — already taught as Assessment and as prevention level. In Planning, USPSTF tells you what belongs on the wellness plan and how strongly to offer it (A/B offer or provide; C selective; D discourage; I explain uncertainty).
When guidelines conflict
The durable example is mammography . Current USPSTF language is biennial screening from ages 40–74 for average-risk women. ACS uses a different start-and-interval pattern (shared decision 40–44, annual 45–54, then biennial or annual, continuing while health and life expectancy support it). Neither document is a blog. The FNP plan: name both if the patient asks, use USPSTF as the default primary-care offer unless the stem names ACS, individualize for higher-than-average risk, and document shared decision-making when the patient chooses the other reasonable U.S. schedule. Cervical screening (USPSTF vs ACS vs ACOG on cotesting intervals) is the same skill.
Do not “split the difference” into a schedule no body published. Do not follow a celebrity podcast over USPSTF. Do not tell the patient that ANCC forbids preference-sensitive choices.
Vignette. A 52-year-old woman has confirmed office and home blood pressures of 148/92, BMI 31, and infrequent asthma symptoms treated for years with albuterol alone. She wants to know whether to start mammograms “every year like my sister’s surgeon said.” The plan is one visit and three owners: 2025 AHA/ACC — start a race-neutral first-line antihypertensive, goal <130/80 , lifestyle, PREVENT discussion; GINA — stop SABA-only, start ICS-formoterol AIR/MART ; USPSTF biennial mammography 40–74 as the default offer, with documented SDM if she prefers the ACS annual pattern. That is guideline-based Planning.
If a stem names an authority, follow that authority. If it does not, follow U.S. primary-care consensus from the condition owner, and write down why.
Loading diagram... Which guideline owns this Planning item?